Does the Time to Start First-Line Treatment Influence the Survival of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma? Results of the MetaSurv-UroCCR 79 Study.

Date publication

juillet 2022

Journal

Clinical genitourinary cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Rolley C, Barthelemy P, Bensalah K, Nouhaud FX, Villers A, Bruyère F, Lebdai S, Ricard S, Gross-Goupil M, Rouprêt M, Bernhard JC, Bigot P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35931600

Résumé

Many patients in the favorable International Metastatic renal cell carcinoma (RCC) Data Base Consortium group (F-MRC) may have a relatively indolent disease course. Surveillance and delay of systemic therapy could be an option in this specific population. However, the question whether this delay could alter patients' outcome remains unanswered. Our objective was to determine if delaying first-line treatment influences the survival of F-MRC patients.

Mots clés

Delayed treatment, Favorable IMDC group, First line treatment, Metastatic renal cell carcinoma

Référence

Clin Genitourin Cancer. 2022 07 9;: